All three models agree that LLY is positioned for upside driven by the Phase 3 TRIUMPH-2 and TRIUMPH-3 retatrutide data showing 22.6% weight loss and the upcoming August 5th Q2 earnings catalyst. Technical momentum is confirmed by all models as price reclaims the $1182-$1189 support zone with rising RSI and MACD indicators, targeting a retest of the $1234-$1245 resistance shelf. One model specifically highlights LLY's history of significant earnings beats (+25.9%, +19.2%) and sector confirmation from XLV as additional tailwinds for a 1-3 week breakout.
All three models warn that LLY is tactically overextended near its 52-week high of $1249.45, with 30-minute RSI levels hitting overbought territory (70+) and price stalling at the upper Bollinger Band. Two models argue the retatrutide catalyst is already priced in, suggesting a low-conviction rally on depressed volume (z-score -2.74) that risks a mean-reversion move toward the $1109-$1155 high-volume nodes. Unique risks include a bearish broader macro regime and upcoming US Q2 GDP data, which could trigger a rejection at the $1200-$1237 resistance zone back toward the $1182 SMA 20 support.
- →A 4h close below $1189.07 or failure to hold the $1182-$1189 support zone signals a breakdown in bullish momentum and confirms a resistance-rejection thesis.
- →A daily close below $1182 or a 4h close below $1164 (loss of SMA20 and structural support) invalidates the support-retest thesis and confirms the bounce has failed.
Individual Model Analysis
Bull/Bear CompetitionWinner: BULL
LLY holds constructive momentum above its rising SMA 20/SMA 50 with a fresh company-specific catalyst — positive Phase 3 retatrutide data (up to 22.6% weight loss) — reinforcing the GLP-1 franchise leadership ahead of Aug 5 Q2 earnings, which has beaten estimates by double digits in three of the last four quarters. Sector (XLV) and rates proxy (TLT) are both confirming the move, supporting a grind toward the 4h resistance at $1234.65 and eventually the 52-week high zone. A pullback-to-support retest near $1189 offers a better-located long entry with room toward resistance.
LLY is extended near its 52-week high (-3.9%) into overhead resistance at $1234-$1244, with the 30-min RSI already at 70 (overbought) and the broad regime confirmed bearish, favoring quality de-risking. A short positioned into the $1230-$1235 resistance zone aims to fade the rally back toward the 4h/1day support cluster near $1182-$1189, capturing mean reversion as momentum exhausts ahead of a two-sided GDP macro event. The setup works if the reclaim stalls at the prior swing high where a prior LLY long already failed on a resistance barrier.
Bull/Bear CompetitionWinner: BULL
LLY is rallying on the back of the fresh retatrutide Phase 3 catalyst (TRIUMPH-2/3, up to 22.6% weight loss) with an FDA filing planned for Q1 2027, providing a fundamental re-rating catalyst that was absent during the prior failed resistance test. Price is pulling back toward the 4h support zone near $1189 after the initial catalyst pop, offering a retest entry ahead of the August 5 earnings report where another beat is expected. The improving 4h MACD crossover, rising RSI from neutral, and confirming sector/rates backdrop support a grind higher through the $1235-1249 resistance zone toward a new all-time high within the 1-3 week swing window.
LLY is rallying on low volume toward the 52-week high after positive retatrutide trial results, but the move is exhausted at 30-min resistance with overbought RSI (70.23) and deeply depressed volume (0th percentile), suggesting the buying lacks conviction. The bearish macro regime (tech weakness, dollar strength, risk-off rotation) creates headwinds for extended mega-cap pharma, and the prior long attempt at this resistance zone failed at $1237.56 on Jul 7. With earnings on Aug 5 as a binary catalyst, fading this low-volume rally into resistance offers a favorable short setup targeting a mean reversion toward the value area low and high-volume node near $1151.
Bull/Bear CompetitionWinner: BULL
LLY presents a compelling long case driven by a fresh catalyst: the Phase 3 TRIUMPH-2 and TRIUMPH-3 trial results for retatrutide, showing average weight loss up to 22.6%, which positions the drug as a potential blockbuster in the obesity market. This news, combined with the upcoming Q2 2026 earnings release on August 5, provides a near-term catalyst for upside repricing. Technically, LLY is showing bullish momentum with RSI rising and MACD histogram turning positive, suggesting further upside potential. The stock is currently trading near support at $1189.07, with a clear path to resistance at $1243.93, aligning with the broader Healthcare sector's strength.
LLY is positioned for a short swing trade due to its extended price location near all-time highs, weakening momentum, and overbought technical conditions. The stock is trading just below its 52-week high of $1249.45 (-3.9%) and faces immediate resistance at $1234.65 (4h) and $1243.93 (1day), with no fresh catalysts to justify a breakout. The broader market regime is bearish, and LLY's recent outperformance lacks confirmation from sector peers, increasing the risk of a pullback toward support at $1140.00 or lower.